Login to Your Account

Idenix crown jewel crumbles as Merck takes $2.9 billion HCV write-down

By Marie Powers
News Editor

Friday, February 24, 2017

Merck and Co. Inc. isn’t exactly ditching its HCV NS5B polymerase inhibitor, known as uprifosbuvir – for now, at least. Enrollment continues in ongoing trials of uprifosbuvir.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription